List of Cubicin drug patents

Cubicin is owned by Cubist Pharms Llc.

Cubicin contains Daptomycin.

Cubicin has a total of 2 drug patents out of which 0 drug patents have expired.

Cubicin was authorised for market use on 12 September, 2003.

Cubicin is available in powder;intravenous dosage forms.

Cubicin can be used as treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis.

The generics of Cubicin are possible to be released after 23 November, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(5 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(7 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic